Last reviewed · How we verify
NCT07314242
A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPD
Phase 2 trial testing Hemay005 tablets in COPD (Chronic Obstructive Pulmonary Disease) in 120 participants. Not yet recruiting.
31 December 2027
Quick facts
| Lead sponsor | Ganzhou Hemay Pharmaceutical Co., Ltd |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 1 January 2026 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2027 |
| Sites | 2 locations across China |
Drugs / interventions tested
- Hemay005 tablets — full drug profile →
- Roflumilast Oral Tablet
- Placebo tablet
Conditions studied
- COPD (Chronic Obstructive Pulmonary Disease) — all drugs for COPD (Chronic Obstructive Pulmonary Disease) →
Sponsor
Ganzhou Hemay Pharmaceutical Co., Ltd — full company profile →
Who can join
40 and older, any sex, with COPD (Chronic Obstructive Pulmonary Disease). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Multicenter, Randomized, Double-blind, Single-dummy, positive drug and placebo-controlled, Parallel Group, Phase 2a Study to Evaluate the Efficacy and Safety of Hemay005 in Adults with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07314242
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Hemay005 tablets
Trials testing the same drug.
- NCT05486104 — Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis · Phase 2 · active not recruiting
Other recruiting trials for COPD (Chronic Obstructive Pulmonary Disease)
Currently open trials in the same condition.
- NCT07406048 — Real-World Effectiveness of a Triple Combination BDP/FF/GB Extrafine in a Single Pressurised Metered Dose Inhaler in Bra · recruiting
- NCT07524023 — Emotional-distress-based Integrated Care Programme in Patients With Stable COPD · NA · recruiting
- NCT07375433 — Heart Failure With Preserved Ejection Fraction in Patients With Сhronic Obstructive Pulmonary Disease: Clinical Course a · recruiting
- NCT07181915 — Changing Outcomes Through Achievement Emails in COPD Using Routine Healthcare Audits · NA · active not recruiting
- NCT07031336 — Photon-counting CT in Chest Imaging · NA · recruiting
Other Ganzhou Hemay Pharmaceutical Co., Ltd trials
Trials by the same sponsor.
- NCT06610890 — Pharmacokinetic Interactions Between Hemay005 Tablets and Midazolam Maleate Tablets · Phase 1 · completed
- NCT06610903 — Bioequivalence Test of Hemay005 Tablets · Phase 1 · completed
- NCT06380153 — To Evaluate the Pharmacokinetics of Hemay005 Tablets in Patients With Renal Impairment · Phase 1 · completed
- NCT06376474 — To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage · Phase 1 · recruiting
- NCT06145893 — A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07314242 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ganzhou Hemay Pharmaceutical Co., Ltd
- Last refreshed: 2 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07314242.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing